Professor Dror Harats founded ImmuneWalk Therapeutics based on more than 30 years of industry experience, with strong background in management of early- to mid-stage biotechnology companies, driving growth from inception to pipeline development and all the way through Phase 3 clinical trials & pre-commercialization. In addition to his multidisciplinary expertise in research, regulatory and clinical development, as CEO, he took a company through NASDAQ listing and raised over $300 million dollars from institutional funds and strategic partners. Prof. Harats is also an experienced consultant specializing in biotechnology and pharmaceutical healthcare companies.